Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19382473 | 0.86 | HDAC1 (0.74) | HDAC1HDAC8HDAC6ALDH1A1PDE4B | |
| SCHEMBL167905 | 0.80 | HDAC1 (0.74) | HDAC1HDAC8HDAC6ALDH1A1PDE4B | |
| SCHEMBL2554554 | 0.80 | HDAC1 (0.74) | HDAC1HDAC8HDAC6ALDH1A1PDE4B | |
| SCHEMBL27768646 | 0.77 | ALDH1A1 (0.74) | HDAC1HDAC8HDAC6ALDH1A1PDE4B | |
| SCHEMBL287420 | 0.77 | ALDH1A1 (0.74) | HDAC1HDAC8HDAC6ALDH1A1PDE4B | |
| SCHEMBL1683862 | 0.76 | ALDH1A1 (0.68) | HDAC1HDAC8HDAC6ALDH1A1PDE4B | |
| SCHEMBL2866244 | 0.74 | HDAC1 (0.71) | HDAC1HDAC8HDAC6ALDH1A1PDE4B | |
| SCHEMBL6706804 | 0.74 | ALDH1A1 (0.70) | HDAC1HDAC8HDAC6ALDH1A1PDE4B | |
| SCHEMBL893099 | 0.74 | ALDH1A1 (1.00) | HDAC1HDAC8HDAC6ALDH1A1PDE4B | |
| SCHEMBL3436645 | 0.74 | HDAC1 (0.65) | HDAC1HDAC8HDAC6ALDH1A1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1019046-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020049316-A1 | Protease inhibitors | HALBERT STACIE MARIE (US) | 2002-04-25 | — | — | US | disclosed |
| EP-1015438-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2000-11-08 | — | — | EP | disclosed |
| EP-1019046-A1 | PROTEASE INHIBITORS | Smithkline Beecham (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-1015438-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0977743-A1 | PROTEASE INHIBITORS | Smithkline Beecham (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1999011637-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-03-11 | — | — | WO | disclosed |
| WO-1998048799-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998049152-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049316-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | HDAC1 313/4885HDAC8 1283/4885HDAC6 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.